title: Immunologic parameters 2 years after high-titer measles immunization in Peruvian children.
abstract: Immunization with high-titer measles vaccines has been associated with excess mortality in children 2-4 years after vaccination. In this study, immunologic parameters in 64 Peruvian children who had been immunized an average of 27 months earlier with high-titer vaccines were compared with parameters in 76 recipients of low-titer vaccines. Delayed-type hypersensitivity, lymphocyte phenotype distributions by flow cytometry, and lymphoproliferation after phytohemagglutinin (PHA) stimulation were assessed. High-titer recipients had smaller indurations to tetanus, diphtheria, and Proteus (P < .05) antigens, decreased PHA stimulation (P = .04), and a lower percentage of CD4+ lymphocytes (P = .04) than low-titer recipients. After adjustment for sex, concurrent illnesses, and other variables in regression analyses, high-titer recipients had a lower percentage of CD4+ lymphocytes (P = .025) and decreased lymphocyte proliferation to PHA (P = .058). These results may provide a clue to the pathogenesis of delayed excess mortality after high-titer measles vaccination in some developing countries.
authors.affiliation: Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.
authors.forename: M E
authors.initials: ME
authors.lastname: León
authors.forename: B
authors.initials: B
authors.lastname: Ward
authors.forename: R
authors.initials: R
authors.lastname: Kanashiro
authors.forename: H
authors.initials: H
authors.lastname: Hernández
authors.forename: S
authors.initials: S
authors.lastname: Berry
authors.forename: A
authors.initials: A
authors.lastname: Vaisberg
authors.forename: J
authors.initials: J
authors.lastname: Escamilla
authors.forename: M
authors.initials: M
authors.lastname: Campos
authors.forename: S
authors.initials: S
authors.lastname: Bellomo
authors.forename: V
authors.initials: V
authors.lastname: Azabache
mesh_terms: D002455:Cell Division; D002675:Child, Preschool; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007223:Infant; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008457:Measles / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D010568:Peru / Q000453:epidemiology; D012727:Sex Characteristics; D016176:T-Lymphocyte Subsets; D014611:Vaccination / Q000401:mortality
chemical_list: D008458:Measles Vaccine